Agonists that stimulate STING-mediated signaling reprogrammed abnormal tumor vasculature toward a normalized vascular structure and displayed synergistically therapeutic efficacy when combined with of VEGFR2 and PD-1 blocking [106]. This evidence concerns the gene STING1 and neoplasm.